BMS, Compugen Pursue Multiple Checkpoint Inhibitions In Antibody Collaboration
Bristol-Myers Squibb is teaming up with Compugen to test the latter’s investigational antibody that targets a new checkpoint, PVRIG, in combination with its own antibody Opdivo. Combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT, is also on the cards for the future.
You may also be interested in...
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals...
It is nearly five years since Compugen signed a deal with Bayer but with AstraZeneca paying $10m up front for a license to develop bispecific and multi-specific antibody products derived from its pipeline, the Tel Aviv-headquartered biotech's computational discovery approach has been validated.